Shots:

• The P-III KEYNOTE-604 study involves assessing of Keytruda (pembrolizumab- 200 mg) + etoposide + Pt CT vs PBO + etoposide +PT CT in 453 patients newly diagnosed with ES-SCLC
• The P-III study resulted in improvement in PFS and OS but the OS results did not meet statistical significance per the pre-specified statistical plan- safety profile was consistent
• Merck & Co's (MSD outside the United States and Canada) Keytruda is a mAb blocking the interaction between PD-1 and its ligands- PD-L1 & PD-L2- activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article

Ref: Merck & Co | Image: Merck